Harvard Apparatus Regenerative Tech Inc  

(Public, NASDAQ:HART)   Watch this stock  
Find more results for JOHN F. MCNAUGHTON
1.14
-0.13 (-10.24%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.06 - 1.25
52 week 1.06 - 8.96
Open 1.24
Vol / Avg. 235,216.00/76,686.00
Mkt cap 11.55M
P/E     -
Div/yield     -
EPS -1.32
Shares 10.13M
Beta     -
Inst. own 39%
Aug 13, 2015
Q2 2015 Harvard Apparatus Regenerative Technology Inc Earnings Call - 5:00PM EDT - Add to calendar
Aug 13, 2015
Q2 2015 Harvard Apparatus Regenerative Technology Inc Earnings Release - 4:00PM EDT - Add to calendar
May 7, 2015
Q1 2015 Harvard Apparatus Regenerative Technology Inc Earnings Call
May 7, 2015
Q1 2015 Harvard Apparatus Regenerative Technology Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -11893.55%
Operating margin - -11889.25%
EBITD margin - -11498.92%
Return on average assets -99.62% -99.34%
Return on average equity -144.42% -105.03%
Employees 24 -
CDP Score - -

Address

84 October Hill Rd Ste 11
HOLLISTON, MA 01746-1371
United States - Map
+1-508-8938999 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Harvard Apparatus Regenerative Technology, Inc. is clinical stage regenerative medicine company developing life-saving medical devices. The Company’s products include Hollow Organ Bioreactors, Solid Organ Bioreactors, Scaffolds, and Clinical Infusion Pump. The Company’s first products are a bioreactor and a synthetic scaffold that can be used by surgeons to create a replacement trachea, or airway, for patients who need an airway transplant. Its bioreactor technology has been used in six human airway transplant surgeries. Its r products are in development. The Company’s products address the critical challenges to trachea transplant, the shortage of suitable donor tracheas. The Company is a wholly owned subsidiary Harvard Bioscience Inc. In October 2013, Harvard Bioscience Inc announced the spin-off of its wholly owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology, Inc.

Officers and directors

John F. Kennedy Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
James J. McGorry President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Thomas McNaughton Jr. Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Saverio La Francesca M.D. Chief Medical Officer
Bio & Compensation  - Reuters
David M. Green Director
Age: 50
Bio & Compensation  - Reuters
John J. Canepa Independent Director
Age: 59
Bio & Compensation  - Reuters
Thomas H. Robinson Independent Director
Age: 56
Bio & Compensation  - Reuters